Table 1.

The main demographic and clinical features of the study population (75 patients with PsA treated with TNF-α blockers). Results are expressed as median/25th–75th percentile unless otherwise indicated.

Variables
Male/female35/40
Age, yrs52/46.75–62
Disease duration, yrs6.5/3–12
Articular manifestations (%)
  Axial50.6
  Peripheral arthritis91.9
  Enthesitis41.4
  Dactylitis22.6
Extraarticular manifestations (%)
  Uveitis5.6
  IBD1.3
DAS28-CRP*3.71/2.7–5.06
DAPSA20.6/13.6–29.6
Tender joint5/2–12
Swollen joint2/0–7
ESR, mm/h23/12.75–29
CRP, mg/dl0.8/0.39–1.2
PtGA52/40–65
VAS pain52.5/40–65
VAS physician45/35–50
HAQ0.75/0.62–1.25
PASI1.3/0–2.05
MASES1/0–2
Concomitant treatment at baseline (%)
  DMARD49 (39.5)
  Prednisone intake39 (31.5)
  NSAID intake99 (79.8)
Anti–TNF-α therapy (%)
  ADA39 (31.4)
  ETA62 (50)
  GOL23 (18.5)
  • PsA: psoriatic arthritis; TNF: tumor necrosis factor; IBD: inflammatory bowel disease; DAS28: 28-joint Disease Activity Score; DAPSA: Disease Activity Index for Psoriatic Arthritis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PtGA: patient’s global assessment; VAS: visual analog scale; HAQ: Health Assessment Questionnaire; PASI: Psoriasis Area and Severity Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal antiinflammatory drugs; ADA: adalimumab; ETA: etanercept; GOL: golimumab.